Delivery Order SPE2DB22D9239-SPE2DB25FDL78
Award Date 9/11/25
Potential Completion Date 10/2/25
Potential Value $3.1K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $4,642.20 to DMS Pharmaceutical Group Inc. for XOLAIR 150 MG/ML Syringe on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. XOLAIR (omalizumab) is a monoclonal antibody used primarily for treating moderate-to-severe allergic asthma and...
- The Defense Logistics Agency awarded a delivery order valued at $6,189.60 to DMS Pharmaceutical Group Inc. for XOLAIR 150 MG/ML syringes. This award, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will fulfill this order. XOLAIR (omalizumab) is a biologic...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $1,547.40 for XOLAIR 75 mg/0.5 ml syringes. The award, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a $27,907.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 mL syringes on September 4, 2025, with an ultimate completion date of September 25, 2025. Xolair (omalizumab) is a monoclonal antibody used primarily to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, making this delivery order part of DLA's pharmaceutical supply chain supporting Department of Defense healthcare facilities. The award...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml auto-injector units. The contract, valued at $10,273.38 with a firm fixed-price structure, was awarded on August 14, 2025, with an ultimate completion date of September 5, 2025. This delivery order was issued without a set-aside designation, and performance will take place at the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml auto-injector on August 13, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order was issued under the SPE2DB Indefinite Delivery Contract (IDC), a $500 million single-award vehicle that enables DLA to procure pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. The...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $22,325.76 with an ultimate completion date of September 16, 2025, was issued without a set-aside designation on August 25, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,547.40 to DMS Pharmaceutical Group Inc. for the supply of XOLAIR 150 mg/ml syringes. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, operates under a firm fixed-price arrangement with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. This $1,547.40 firm fixed-price delivery order was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on the open market despite its small business status. Xolair...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...